NEOLEUKIN THERAPEUTICS, INC.
188 East Blaine Street
Suite 450
Seattle, WA 98102
May 16, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: Jason | Drory |
Office of Life Sciences
| Re: | Neoleukin Therapeutics, Inc. |
Registration Statement on Form S-3
Filed May 9, 2022
File No. 333-264803
Via EDGAR - Acceleration Request
Requested Date: May 18, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Neoleukin Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| NEOLEUKIN THERAPEUTICS, INC. | ||
| By: | /s/ Jonathan G. Drachman | |
| Jonathan G. Drachman | ||
| Chief Executive Officer | ||
| cc: | Robert A. Freedman, Esq. | |
| Julia Forbess, Esq. | ||
| Fenwick & West LLP |